Skip to main content

This artificial heart could help keep people on transplant waiting lists alive

Carmat TAH 3D video - Presentation

A French company called Carmat has created an artificial heart that could potentially help save the lives of people with end-stage biventricular heart failure. And, no, this isn’t some piece of future tech that won’t be available for another decade or so; it has already been used on actual patients — including one who  had the implanted heart two years ago. And it’s coming to the United States.

“The idea behind this heart, which was born nearly 30 years ago, was to create a device which would replace heart transplants, a device that works physiologically like a human heart, one that’s pulsating, self-regulated, and compatible with blood,” Carmat CEO Stéphane Piat recently told Reuters.

The artificial heart, which weighs about three times what the average human heart weighs, boasts two ventricles — one for blood, the other for hydraulic fluid — separated by a membrane. Hydraulic fluid is moved in and out using a motorized pump, which moves the membrane so that the blood can flow. In-built electronics, sensors, and microprocessors can autonomously regulate the blood flow in response to the activity of the patient, who must carry a bag of actuator fluid, a lithium-ion battery, and a controller.


“Carmat aims to meet a major public health challenge related to cardiovascular diseases, namely heart failure, the leading cause of death in the world,” the company notes on its website. “More specifically, Carmat aims to provide a lasting solution to the treatment of terminal heart failure, a disease for which there are very few effective options today, the main one being heart transplants.”

The artificial heart has reportedly received the necessary CE marking in Europe to show that it is in line with health and safety standards. It received this approval last year, and will launch in both Germany and France in the second quarter of 2021. According to SingularityHub, Carmat has also received U.S. Food and Drug Administration permission for an early feasibility study in the United States. That will take place this year as well.

With thousands of biventricular heart failure patients currently on transplant waiting lists around the world, this could be a massive game changer that helps solve a major real-world problem.

Editors' Recommendations

Luke Dormehl
I'm a UK-based tech writer covering Cool Tech at Digital Trends. I've also written for Fast Company, Wired, the Guardian…
Watch how the iPhone 15 handles the bend test that busted the Pro Max
YouTuber Zack Nelson bending an iPhone 15 to test its strength.

Earlier this week, we reported how popular tech YouTuber Zack Nelson busted the back of an iPhone 15 Pro Max when he subjected it to his bend test.

The back glass shattered with relatively little effort, which came as a great surprise not only to Nelson but to everyone watching, too.

Read more
NASA’s record-breaking astronaut arrives home safely
NASA astronaut Frank Rubio shortly after returning to Earth in September 2023.

NASA astronaut Frank Rubio shortly after returning to Earth after becoming the first American astronaut to spend a full year in orbit. NASA

Frank Rubio has arrived home safely after spending 371 days in space -- a record for a NASA astronaut.

Read more
Meta pays big bucks to end office lease that still had 18 years left
A silhouetted person holds a smartphone displaying the Facebook logo. They are standing in front of a sign showing the Meta logo.

Meta had a big headline-grabbing event on Wednesday, unveiling new gear and talking up its plans for the future.

What it definitely didn’t mention was that it recently paid a large sum of money to end a lease on a major office development in London, despite it having another 18 years to run.

Read more